309 related articles for article (PubMed ID: 25752159)
21. Pfizer explores rare disease path.
Shaffer C
Nat Biotechnol; 2010 Sep; 28(9):881-2. PubMed ID: 20829809
[No Abstract] [Full Text] [Related]
22. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
23. EU to review rare disease drugs market exclusivity.
Sheridan C
Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
[No Abstract] [Full Text] [Related]
24. Policymaking for Orphan Drugs and Its Challenges.
Rhee TG
AMA J Ethics; 2015 Aug; 17(8):776-9. PubMed ID: 26270879
[No Abstract] [Full Text] [Related]
25. Does orphan drug legislation really answer the needs of patients?
Haffner ME; Torrent-Farnell J; Maher PD
Lancet; 2008 Jun; 371(9629):2041-4. PubMed ID: 18555916
[No Abstract] [Full Text] [Related]
26. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
27. [European incentives for orphan medicinal products].
Enzmann H; Lütz J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
[TBL] [Abstract][Full Text] [Related]
28. The challenges of orphan drugs and orphan diseases: real and imagined.
Hudson I; Breckenridge A
Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
[TBL] [Abstract][Full Text] [Related]
29. Fair pricing of "old" orphan drugs: considerations for Canada's orphan drug policy.
Roberts EA; Herder M; Hollis A
CMAJ; 2015 Apr; 187(6):422-425. PubMed ID: 25712953
[No Abstract] [Full Text] [Related]
30. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.
Dear JW; Lilitkarntakul P; Webb DJ
Br J Clin Pharmacol; 2006 Sep; 62(3):264-71. PubMed ID: 16934041
[TBL] [Abstract][Full Text] [Related]
31. [Drugs for rare diseases: the blessing of being orphans.].
Costa E; Schieppati A; Luzzatto L; Remuzzi G
Recenti Prog Med; 2019 May; 110(5):221-229. PubMed ID: 31140454
[TBL] [Abstract][Full Text] [Related]
32. Support system: through charities, drug makers help people--and themselves.
Anand G
Wall St J (East Ed); 2005 Dec; ():A1, A10. PubMed ID: 16502554
[No Abstract] [Full Text] [Related]
33. Law and research could add up to profitable niche drugs.
Haefner B
Nature; 2007 Apr; 446(7138):856. PubMed ID: 17443162
[No Abstract] [Full Text] [Related]
34. Policy alternatives for treatments for rare diseases.
Panju AH; Bell CM
CMAJ; 2010 Nov; 182(17):E787-92. PubMed ID: 20624867
[No Abstract] [Full Text] [Related]
35. R&D policy, agency costs and innovation in personalized medicine.
Yin W
J Health Econ; 2009 Sep; 28(5):950-62. PubMed ID: 19671480
[TBL] [Abstract][Full Text] [Related]
36. Limits on use of health economic assessments for rare diseases.
Hyry HI; Stern AD; Cox TM; Roos JC
QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281
[TBL] [Abstract][Full Text] [Related]
37. Competing for public funding of medicines to treat rare disorders in New Zealand.
Crausaz S
Bull World Health Organ; 2015 Feb; 93(2):67. PubMed ID: 25883396
[No Abstract] [Full Text] [Related]
38. Translation of rare disease research into orphan drug development: disease matters.
Heemstra HE; van Weely S; Büller HA; Leufkens HG; de Vrueh RL
Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412
[TBL] [Abstract][Full Text] [Related]
39. A new era of hope for the world's most neglected diseases.
The
PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
[TBL] [Abstract][Full Text] [Related]
40. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]